IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
Gilead Sets Price at $3,120 Per Patient With Private Insurance for Coronavirus Drug Remdesivir
Reporting
— Jun 29, 2020
Gilead Sciences unveiled the cost of its five-day coronavirus treatment. On Monday, Gilead Chairman and CEO Daniel O’Day penned an open letter outlining the costs for remdesivir treatments. The cost will be $2,340 per…
0
Share
US Emergency Approval Broadens Use of Gilead’s COVID-19 Drug Remdesivir
Reporting
— May 2, 2020
Gilead Science Inc’s <GILD.O> antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in more…
0
Share
Gilead’s Remdesivir Gets US FDA Approval for Hospitalized COVID-19 Patients
Reporting
— Oct 22, 2020
The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in…
0
Share
State Attorneys General Urge US Government to Increase Supply, Lower Price of Remdesivir
Reporting
— Aug 4, 2020
A bipartisan coalition of attorneys general on Tuesday urged the U.S. government to use its legal authority to increase the availability and lower the price of Gilead Sciences’ COVID-19 treatment, remdesivir. Gilead has…
0
Share
IJR
House GOP Blocks Thomas Massie’s Attempt To Impeach Pete Hegseth
Nicole Silverio · 4 min · 9h
Gilead Says Remdesivir Shows Improvement in COVID-19 Patients When Used Early
Reporting
— Apr 29, 2020
Gilead Sciences Inc on Wednesday said its experimental antiviral drug remdesivir helped improve outcomes for patients with COVID-19, and provided data suggesting it worked better when given earlier in the course of…
0
Share
Most Influential Women in World History
Yourlist
— Ranking
From ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.
Share
Warren and Sanders Rip Trump for ‘Windfall’ Deal Given to Gilead For Remdesivir
Reporting
— Jul 16, 2020
Sens. Elizabeth Warren (D-Mass.), Bernie Sanders (I-Vt.) and several other Democratic lawmakers are pushing back against President Donald Trump’s administration for its “windfall” deal with Gilead Sciences to acquire…
0
Share
Fauci Says Leak Concerns Fueled His White House Revelation of Gilead Drug Results
Reporting
— Apr 30, 2020
Concerns over leaks compelled the top U.S. infectious disease official to reveal data on Gilead Sciences Inc’s experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in…
0
Share
Rand Paul Offers Explanation for 16 Months Late Disclosure of Wife’s Stock Purchase
Reporting
— Aug 13, 2021
Sen. Rand Paul (R-Ky.) says he tried to file paperwork to disclose his wife’s investment in Gilead Sciences. But, the Kentucky senator said he failed to hit “send” on the paperwork. On Wednesday, Paul disclosed in a…
0
Share
Wall Street Jumps on Coronavirus Drug Hopes; Fed in Focus
Reporting
— Apr 29, 2020
U.S. stocks jumped to seven-week highs on Wednesday as Gilead Sciences gave an encouraging update on a potential COVID-19 treatment and upbeat earnings from Google-parent Alphabet boosted the so-called market-leading…
0
Share
FaithTap
Jordan Wins Minority Leader Spot, Besting Scalise
House Judiciary Committee Chairman Jim Jordan (R-Ohio) was voted in as minority leader Tuesday a closed-door election. Sources told Fox News Digital Jordan defeated Majority Leade… — by Sandra Rhodes
4m
Share
Gilead, Merck Report Weekly HIV Trial Results
Health
— Jul 21, 2026
Gilead Sciences and Merck reported positive Phase 3 results for their once-weekly oral HIV regimen combining islatravir and lenacapavir, showing non-inferiority to existing daily therapies and maintaining viral suppression through 48 weeks in virologically suppressed patients. The ISLEND-1 and ISLEND-2 trials suggest this two-drug regimen could become the first complete weekly HIV treatment, with a safety profile generally comparable to current options and plans for regulatory submissions.
+3
0
Share
